Depemokimab in chronic rhinosinusitis with nasal polyps: A turning point or a missed opportunity?

Enrico Heffler; Giovanni Paoletti

doi:10.1016/j.medj.2025.100674

Depemokimab in chronic rhinosinusitis with nasal polyps: A turning point or a missed opportunity?

Med. 2025 May 9;6(5):100674. doi: 10.1016/j.medj.2025.100674.

Authors

Enrico Heffler¹, Giovanni Paoletti²

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy; Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy. Electronic address: enrico.heffler@hunimed.eu.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy; Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.

PMID: 40347936
DOI: 10.1016/j.medj.2025.100674

Abstract

The ANCHOR-1 and ANCHOR-2 trials of the long-acting anti-interleukin (IL)-5 monoclonal antibody depemokibab in chronic rhinosinusitis with nasal polyposis demonstrated the safety and statistical efficacy of the drug compared to placebo.¹ However, its clinical benefits appear limited compared to other biologic therapies. The reduced dosing interval may improve adherence, but further research is needed to identify the most responsive patients.

MeSH terms

Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / therapeutic use
Chronic Disease
Humans
Interleukin-5 / antagonists & inhibitors
Nasal Polyps* / complications
Nasal Polyps* / drug therapy
Rhinitis* / complications
Rhinitis* / drug therapy
Rhinosinusitis
Sinusitis* / complications
Sinusitis* / drug therapy
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Interleukin-5